Maud Maho‐Vaillant

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

P. Joly, Maud Maho‐Vaillant, C. Prost‐Squarcioni et al. · The Lancet · 2017 · 586 citations

Ritux 3, Pharmacology, Pharmacotherapy +2

Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response

Natacha Colliou, D Picard, Frédérique Caillot et al. · Science Translational Medicine · 2013 · 238 citations

IL‐10 produced by activated human B cells regulates CD4⁺ T‐cell activation <i>in vitro</i>

Jean‐David Bouaziz, Sébastien Calbo, Maud Maho‐Vaillant et al. · European Journal of Immunology · 2010 · 226 citations · Full text

CD11c+ B Cells Are Mainly Memory Cells, Precursors of Antibody Secreting Cells in Healthy Donors

Marie-Laure Golinski, Mélanie Demeules, Céline Derambure et al. · Frontiers in Immunology · 2020 · 144 citations · Full text

Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid‐sparing effect

D.M. Chen, Adefowope Odueyungbo, Eva Csinady et al. · British Journal of Dermatology · 2019 · 91 citations · Full text